重组人促红细胞生成素治疗重度创伤性脑损伤
Recombinant human erythropoietin for treating severe traumatic brain injury.
作者信息
Bai Xiao-Fei, Gao Yong-Kai
机构信息
Department of Neurosurgery, The People's Hospital of Yan'an, Yan'an, Shaanxi, China.
出版信息
Medicine (Baltimore). 2018 Jan;97(1):e9532. doi: 10.1097/MD.0000000000009532.
Abstract
BACKGROUND
This study aimed to explore the efficacy and safety of recombinant human erythropoietin (RHE) for the treatment of severe traumatic brain injury (STBI).
METHODS
One hundred and twenty eligible patients with STBI were randomly divided into an intervention group or a control group equally. Patients in the intervention group received RHE. The participants in the control group received 0.9% saline. The outcome measurements included the Glasgow Outcome Scale (GOS) scores, mortality, and any adverse events.
RESULTS
At the end of 10-week follow-up after treatment, RHE neither showed greater efficacy in GOS scores (1-2, P = .43; 3-4, P = .25; 5-6, P = .58; 7-8, P = .23), nor the lower mortality in the intervention group than those in the control group (P = .47). In addition, both groups had similar safety profile.
CONCLUSION
This study found that RHE did not improve the neurological outcomes in patients with STBI.
摘要
背景
本研究旨在探讨重组人促红细胞生成素（RHE）治疗重度创伤性脑损伤（STBI）的疗效和安全性。
方法
120例符合条件的STBI患者被随机均分为干预组和对照组。干预组患者接受RHE治疗。对照组参与者接受0.9%生理盐水治疗。结局指标包括格拉斯哥预后量表（GOS）评分、死亡率和任何不良事件。
结果
治疗后10周随访结束时，RHE在GOS评分方面既未显示出更高的疗效（1 - 2分，P = 0.43；3 - 4分，P = 0.25；5 - 6分，P = 0.58；7 - 8分，P = 0.23），干预组的死亡率也不比对照组低（P = 0.47）。此外，两组的安全性相似。
结论
本研究发现，RHE并未改善STBI患者的神经学结局。
相似文献
1
Recombinant human erythropoietin for treating severe traumatic brain injury.
Medicine (Baltimore). 2018 Jan;97(1):e9532. doi: 10.1097/MD.0000000000009532.
2
Recombinant human erythropoietin improves functional recovery in patients with severe traumatic brain injury: A randomized, double blind and controlled clinical trial.
Clin Neurol Neurosurg. 2016 Nov;150:80-83. doi: 10.1016/j.clineuro.2016.09.001. Epub 2016 Sep 3.
3
Erythropoietin in traumatic brain injury (EPO-TBI): a double-blind randomised controlled trial.
Lancet. 2015 Dec 19;386(10012):2499-506. doi: 10.1016/S0140-6736(15)00386-4. Epub 2015 Oct 6.
4
A randomized placebo-controlled trial of progesterone with or without hypothermia in patients with acute severe traumatic brain injury.
Neurol India. 2017 Nov-Dec;65(6):1304-1311. doi: 10.4103/0028-3886.217973.
5
Therapeutic effect of erythropoietin in patients with traumatic brain injury: a meta-analysis of randomized controlled trials.
J Neurosurg. 2017 Jul;127(1):8-15. doi: 10.3171/2016.4.JNS152909. Epub 2016 Jul 1.
6
Neuroprotective Effects of Erythropoietin in Patients with Severe Closed Brain Injury.
Turk Neurosurg. 2015;25(4):552-8. doi: 10.5137/1019-5149.JTN.9685-14.4.
7
IMPACT probability of poor outcome and plasma cytokine concentrations are associated with multiple organ dysfunction syndrome following traumatic brain injury.
J Neurosurg. 2019 Jan 11;131(6):1931-1937. doi: 10.3171/2018.8.JNS18676. Print 2019 Dec 1.
8
Erythropoietin in patients with traumatic brain injury and extracranial injury-A post hoc analysis of the erythropoietin traumatic brain injury trial.
J Trauma Acute Care Surg. 2017 Sep;83(3):449-456. doi: 10.1097/TA.0000000000001594.
9
Hypertonic saline versus other intracranial pressure-lowering agents for people with acute traumatic brain injury.
Cochrane Database Syst Rev. 2020 Jan 17;1(1):CD010904. doi: 10.1002/14651858.CD010904.pub3.
10
Serum biomarkers as predictors of long-term outcome in severe traumatic brain injury: analysis from a randomized placebo-controlled Phase II clinical trial.
J Neurosurg. 2016 Sep;125(3):631-41. doi: 10.3171/2015.6.JNS15674. Epub 2016 Jan 1.
引用本文的文献
1
Emerging therapies for immunomodulation in traumatic brain injury: A systematic review and meta-analysis.
Surg Neurol Int. 2024 Sep 13;15:327. doi: 10.25259/SNI_502_2024. eCollection 2024.
2
Effect of erythropoietin on SOFA score, Glasgow Coma Scale and mortality in traumatic brain injury patients: a randomized-double-blind controlled trial.
Ann Med Surg (Lond). 2024 May 15;86(7):3990-3997. doi: 10.1097/MS9.0000000000002143. eCollection 2024 Jul.
3
Pharmacological components with neuroprotective effects in the management of traumatic brain injury: evidence from network meta-analysis.
Neurol Sci. 2023 May;44(5):1665-1678. doi: 10.1007/s10072-023-06600-7. Epub 2023 Jan 16.
4
Comparative safety of multiple doses of erythropoietin for the treatment of traumatic brain injury: A systematic review and network meta-analysis.
Front Neurol. 2022 Dec 13;13:998320. doi: 10.3389/fneur.2022.998320. eCollection 2022.
5
Effect of drug therapy on nerve repair of moderate-severe traumatic brain injury: A network meta-analysis.
Front Pharmacol. 2022 Nov 2;13:1021653. doi: 10.3389/fphar.2022.1021653. eCollection 2022.
6
Current and Potential Pharmacologic Therapies for Traumatic Brain Injury.
Pharmaceuticals (Basel). 2022 Jul 6;15(7):838. doi: 10.3390/ph15070838.
7
A Retrospective Analysis of Randomized Controlled Trials on Traumatic Brain Injury: Evaluation of CONSORT Item Adherence.
Brain Sci. 2021 Nov 13;11(11):1504. doi: 10.3390/brainsci11111504.
8
Potential Efficacy of Erythropoietin on Reducing the Risk of Mortality in Patients with Traumatic Brain Injury: A Systematic Review and Meta-Analysis.
Biomed Res Int. 2020 Oct 29;2020:7563868. doi: 10.1155/2020/7563868. eCollection 2020.
9
Efficacy and safety of erythropoietin for traumatic brain injury.
BMC Neurol. 2020 Nov 2;20(1):399. doi: 10.1186/s12883-020-01958-z.
10
Drugs with anti-inflammatory effects to improve outcome of traumatic brain injury: a meta-analysis.
Sci Rep. 2020 Sep 30;10(1):16179. doi: 10.1038/s41598-020-73227-5.
本文引用的文献
1
Intensive insulin therapy for preventing postoperative infection in patients with traumatic brain injury: A randomized controlled trial.
Medicine (Baltimore). 2017 Mar;96(13):e6458. doi: 10.1097/MD.0000000000006458.
2
Rehabilitation needs and participation restriction in patients with cognitive disorder in the chronic phase of traumatic brain injury.
Medicine (Baltimore). 2017 Jan;96(4):e5968. doi: 10.1097/MD.0000000000005968.
3
Epidemiology and clinical characteristics of traumatic brain injury in Lebanon: A systematic review.
Medicine (Baltimore). 2016 Nov;95(47):e5342. doi: 10.1097/MD.0000000000005342.
4
Recombinant human erythropoietin improves functional recovery in patients with severe traumatic brain injury: A randomized, double blind and controlled clinical trial.
Clin Neurol Neurosurg. 2016 Nov;150:80-83. doi: 10.1016/j.clineuro.2016.09.001. Epub 2016 Sep 3.
5
Relation between injury of the periaqueductal gray and central pain in patients with mild traumatic brain injury: Observational study.
Medicine (Baltimore). 2016 Jun;95(26):e4017. doi: 10.1097/MD.0000000000004017.
6
Impact of Intracranial Pressure Monitoring on Prognosis of Patients With Severe Traumatic Brain Injury: A PRISMA Systematic Review and Meta-Analysis.
Medicine (Baltimore). 2016 Feb;95(7):e2827. doi: 10.1097/MD.0000000000002827.
7
Outcomes of Early Decompressive Craniectomy Versus Conventional Medical Management After Severe Traumatic Brain Injury: A Systematic Review and Meta-Analysis.
Medicine (Baltimore). 2015 Oct;94(43):e1733. doi: 10.1097/MD.0000000000001733.
8
Erythropoietin in traumatic brain injury (EPO-TBI): a double-blind randomised controlled trial.
Lancet. 2015 Dec 19;386(10012):2499-506. doi: 10.1016/S0140-6736(15)00386-4. Epub 2015 Oct 6.
9
Recombinant human erythropoietin improves the neurofunctional recovery of rats following traumatic brain injury via an increase in circulating endothelial progenitor cells.
Transl Stroke Res. 2015 Feb;6(1):50-9. doi: 10.1007/s12975-014-0362-x. Epub 2014 Aug 3.
10
Neuroprotective role of erythropoietin in neonates.
J Matern Fetal Neonatal Med. 2012 Oct;25 Suppl 4:105-7. doi: 10.3109/14767058.2012.715025.
Zotero 插件